Form 4: Charles River Laboratories Director Paul Graves Acquires Equity and Options Valued at Over $400,000

Paul W. Graves, a Director at Charles River Laboratories International, Inc. (CRL), acquired 946 shares of common stock and 2,082 stock options on June 2, 2025, as part of his compensation, totaling an acquisition value of approximately $408,900 based on the transaction price.

Summary

• Paul W. Graves, a Director of Charles River Laboratories International, Inc. (CRL), reported an acquisition of securities on June 2, 2025.
• Mr. Graves acquired 946 shares of common stock in the form of unvested restricted stock units (RSUs) at a price of $135.04 per share, totaling approximately $127,700.
• These RSUs are set to vest on the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Additionally, Mr. Graves acquired 2,082 stock options with an exercise price of $135.04 per share, representing an acquisition value of approximately $281,200.
• These stock options become exercisable on the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders, and are set to expire on June 2, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The acquisition of equity by a director aligns their interests with shareholders, which is generally viewed favorably. However, it is a routine compensation disclosure and not indicative of specific operational performance or strategic shifts.

Positives

• Director Paul W. Graves acquired additional equity and options in the company, which aligns his interests with those of shareholders.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and compliant acquisition strategy.

Risks

• The value of the acquired common stock and stock options is subject to market fluctuations of Charles River Laboratories International, Inc. (CRL) shares.
• The full benefit of the restricted stock units and stock options is contingent upon future vesting and exercisability dates, meaning the value is not immediately realized.

Future Outlook

This document is a disclosure of an insider equity acquisition and does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This Form 4 filing represents a routine disclosure of an insider equity acquisition, which is a common practice across all industries for publicly traded companies as part of executive and director compensation packages. It does not provide specific insights into broader industry trends or competitive dynamics within the life sciences or contract research organization (CRO) sector.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as components of director compensation is a standard practice across publicly traded companies, aligning director incentives with shareholder value creation.
• The filing of a Form 4 for such transactions is a regulatory requirement for all U.S. public companies, ensuring transparency in insider holdings and transactions.

Corporate Governance

Related Party Transactions

• The acquisition of common stock and stock options by Paul W. Graves, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The acquisition of additional equity by a director aligns their financial interests with those of the shareholders, potentially signaling confidence in the company's long-term prospects.

Next Steps

• Vesting of 946 restricted stock units on the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Stock options for 2,082 shares becoming exercisable on the earlier of June 2, 2026, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, Insider Transaction, Paul Graves, Director, Stock Options, Restricted Stock Units, Equity Compensation, SEC Filing, Rule 10b5-1